IL197986A0 - Ketoconazole enantiomer in humans - Google Patents

Ketoconazole enantiomer in humans

Info

Publication number
IL197986A0
IL197986A0 IL197986A IL19798609A IL197986A0 IL 197986 A0 IL197986 A0 IL 197986A0 IL 197986 A IL197986 A IL 197986A IL 19798609 A IL19798609 A IL 19798609A IL 197986 A0 IL197986 A0 IL 197986A0
Authority
IL
Israel
Prior art keywords
humans
ketoconazole enantiomer
ketoconazole
enantiomer
Prior art date
Application number
IL197986A
Other languages
English (en)
Original Assignee
Cortendo Invest Ab
Timothy Andrew Stewart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Invest Ab, Timothy Andrew Stewart filed Critical Cortendo Invest Ab
Publication of IL197986A0 publication Critical patent/IL197986A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL197986A 2006-10-02 2009-04-05 Ketoconazole enantiomer in humans IL197986A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896306P 2006-10-02 2006-10-02
PCT/US2007/080186 WO2008042898A2 (en) 2006-10-02 2007-10-02 Ketoconazole enantiomer in humans

Publications (1)

Publication Number Publication Date
IL197986A0 true IL197986A0 (en) 2009-12-24

Family

ID=39269161

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197986A IL197986A0 (en) 2006-10-02 2009-04-05 Ketoconazole enantiomer in humans

Country Status (12)

Country Link
US (4) US9198906B2 (https=)
EP (1) EP2076265A4 (https=)
JP (1) JP2010505866A (https=)
AU (1) AU2007303219A1 (https=)
BR (1) BRPI0719835A2 (https=)
CA (1) CA2664800A1 (https=)
IL (1) IL197986A0 (https=)
NO (1) NO20091593L (https=)
NZ (1) NZ576569A (https=)
RU (1) RU2009116632A (https=)
WO (1) WO2008042898A2 (https=)
ZA (1) ZA200902127B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006204334B2 (en) * 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
CA2637000A1 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
EP3049084A4 (en) * 2013-09-25 2017-03-15 Cortendo AB (publ) Novel functionalized 5-(phenoxymethyl)-1,3-dioxane analogs exhibitng cytochrome p450 inhibition
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
JP7574204B2 (ja) 2019-03-04 2024-10-28 ストロングブリッジ ダブリン リミテッド レボケトコナゾールによる疾患の処置方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144346A (en) 1977-01-31 1979-03-13 Janssen Pharmaceutica N.V. Novel 1-(1,3-dioxolan-2-ylmethyl)-1H-imidazoles
US4503055A (en) 1979-03-26 1985-03-05 Janssen Pharmaceutica, N.V. Derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5432176A (en) 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
AU5955094A (en) * 1992-12-22 1994-07-19 Sepracor, Inc. Methods and compositions of (-) ketoconazole for treating fungal yeast and dermatophyte infections
AU5851594A (en) 1992-12-22 1994-07-19 Georgetown University Methods and compositions of (+) ketoconazole for treating fungal, yeast and dermatophyte infections
IL109728A0 (en) 1993-05-28 1994-08-26 Pfizer Res & Dev Indoles
US5869255A (en) 1994-02-01 1999-02-09 The Regents Of The University Of California Probes labeled with energy transfer couples dyes exemplified with DNA fragment analysis
US6642236B1 (en) 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
WO1996004912A1 (en) 1994-08-09 1996-02-22 Metabolic Syndrome I Gbg Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5584790A (en) 1995-09-08 1996-12-17 Beckman Instruments, Inc. Variable inclination centrifugation assembly for rapid separation of blood
WO1997021435A1 (en) 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
US5994334A (en) 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
BR9810378A (pt) 1997-07-01 2000-08-29 Novo Nordisk As Composto,uso do mesmo, composição farmacêutica, e, processos de tratar a diabete do tipo i ou do tipo ii, de tratar a hiperglicemia, e de diminuir a glicose do sangue em um mamìfero
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
US6921748B1 (en) 1999-03-29 2005-07-26 Uutech Limited Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes
CA2369549A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
DE60023492T2 (de) 1999-05-17 2006-07-20 Novo Nordisk A/S Glucagon antagonisten/inverse agonisten
GB9915625D0 (en) 1999-07-02 1999-09-01 Cortendo Ab Method
CA2379604A1 (en) 1999-09-28 2001-04-05 Bayer Corporation Pituitary adenylate cyclase activating peptide (pacap) receptor 3 (r3) agonists and their pharmacological methods of use
US20020055512A1 (en) 2000-01-21 2002-05-09 Cortendo Ab. Compositions for delivery of a cortisol antagonist
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
WO2002000681A1 (en) 2000-06-27 2002-01-03 Aventis Pharma S.A. 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
GB0118300D0 (en) 2001-07-26 2001-09-19 Cortendo Ab Formulations
AU2002337119A1 (en) 2001-09-21 2003-04-07 Bayer Healthcare Ag Regulation of human steroid 5-alpha reductase
CA2459926A1 (en) 2001-09-24 2003-04-03 Merck & Co., Inc. Screening and selection methods for statin drug combinations
EP1432706A2 (en) 2001-09-26 2004-06-30 Bayer Pharmaceuticals Corporation 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
JP2005519927A (ja) 2002-02-07 2005-07-07 ファイザー・インク 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
EP1581247A4 (en) 2002-12-11 2007-09-12 Amylin Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING STEIN-LEVENTHAL SYNDROME
WO2004080414A2 (en) 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
WO2005113516A1 (en) 2004-05-14 2005-12-01 Neurocrine Biosciences, Inc. Uracil-type gonadotropin-releasing hormone receptor antagonists and methods related thereto
US20060002999A1 (en) 2004-06-17 2006-01-05 Forest Laboratories, Inc. Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2006204334B2 (en) 2005-01-10 2012-02-23 Cortendo Ab (Publ) Methods and compositions for treating diabetes, metabolic syndrome and other conditions
US20070116839A1 (en) * 2005-11-23 2007-05-24 The Coca-Cola Company High-Potency Sweetener Composition With C-Reactive Protein Reducing Substance and Compositions Sweetened Therewith
CA2637000A1 (en) 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
AU2007303219A1 (en) 2006-10-02 2008-04-10 Cortendo Ab (Publ) Ketoconazole enantiomer in humans
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases

Also Published As

Publication number Publication date
JP2010505866A (ja) 2010-02-25
BRPI0719835A2 (pt) 2014-05-06
WO2008042898A9 (en) 2008-09-04
ZA200902127B (en) 2010-07-28
US20100093755A1 (en) 2010-04-15
EP2076265A4 (en) 2010-09-22
CA2664800A1 (en) 2008-04-10
WO2008042898A2 (en) 2008-04-10
NZ576569A (en) 2012-05-25
US20190209555A1 (en) 2019-07-11
NO20091593L (no) 2009-04-22
US9198906B2 (en) 2015-12-01
US20160067243A1 (en) 2016-03-10
EP2076265A2 (en) 2009-07-08
AU2007303219A1 (en) 2008-04-10
US20180125841A1 (en) 2018-05-10
RU2009116632A (ru) 2010-11-10
WO2008042898A3 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
GB0720748D0 (en) Dynamic heardrest
GB0603781D0 (en) Application verification
ZA200808932B (en) Preservative
IL197986A0 (en) Ketoconazole enantiomer in humans
GB0612542D0 (en) Combinations comprising staurosporines
PL2074258T3 (pl) Płyta pilśniowa
GB0600967D0 (en) Methods
GB0613209D0 (en) Methods
GB0601699D0 (en) Method
GB0601979D0 (en) Rests
GB0608941D0 (en) Methods
GB0623293D0 (en) Creating fingerprints
GB0622952D0 (en) Tree-less saddles
GB0603036D0 (en) Method
HK1132459A (en) Ketoconazole enantiomer in humans
GB0610059D0 (en) Uses and methods
GB0625861D0 (en) Modified flexicast/flexisplint
GB0603533D0 (en) Easy-hold reins
GB0618154D0 (en) Concept eight
AU313485S (en) OBSP bed
GB0617888D0 (en) Bed
AU311596S (en) Bed
GB0616344D0 (en) Bed
GB0611920D0 (en) W w w
GB0609731D0 (en) W w w